CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
CytomX Therapeutics (CTMX) Misses Q3 EPS by 2c
November 8, 2022 4:19 PM ESTCytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $16.92 million versus the consensus estimate of $18.27 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
... More